CN107536921B - Traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof - Google Patents
Traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof Download PDFInfo
- Publication number
- CN107536921B CN107536921B CN201710877861.1A CN201710877861A CN107536921B CN 107536921 B CN107536921 B CN 107536921B CN 201710877861 A CN201710877861 A CN 201710877861A CN 107536921 B CN107536921 B CN 107536921B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract description 23
- 208000020346 hyperlipoproteinemia Diseases 0.000 title abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 35
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 210000002966 serum Anatomy 0.000 claims abstract description 24
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 21
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 21
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 21
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 21
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 21
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 21
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 21
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 21
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 21
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 21
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 19
- 108010023302 HDL Cholesterol Proteins 0.000 claims abstract description 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 230000001603 reducing effect Effects 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 235000020374 simple syrup Nutrition 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000009200 high fat diet Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 241001092040 Crataegus Species 0.000 description 19
- 238000007796 conventional method Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 239000013641 positive control Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 241000125175 Angelica Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010068961 Hypo HDL cholesterolaemia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating hyperlipoproteinemia, which is prepared from the following raw material medicines in parts by weight: 90-110 parts of fructus trichosanthis, 90-110 parts of rhizoma alismatis, 140 parts of raw hawthorn, 90-110 parts of angelica sinensis and 90-110 parts of semen cassiae. Experiments show that the traditional Chinese medicine composition can obviously reduce the serum total cholesterol and triglyceride levels of a hyperlipemia animal model, and simultaneously increase the serum HDL-C, which indicates that the traditional Chinese medicine composition has obvious lipid-lowering efficacy, and the lipid-lowering effect is more obvious under the same dosage level. The lipid-lowering medicine has the advantages of few medicine ingredients, low price and simple preparation, and is a safe and effective lipid-lowering medicine.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof.
Background
Hyperlipoproteinemia (hyperlipoproteinemia) is a condition known as hyperlipidemia, which refers to an increased level of cholesterol and/or triglycerides in the serum. Generally, the total cholesterol in the fasting serum of an adult exceeds 5.72mmol/L, the triglyceride exceeds 1.70mmol/L, and the hyperlipidemia can be diagnosed. Hyperlipidemia is common in middle-aged and elderly people, and the onset age of the hyperlipidemia tends to advance year by year, and patients with prolonged severe disease can have symptoms such as dizziness, headache, debilitation, palpitation, limb numbness, chest distress, chest pain, etc. They can be simply classified according to different types: hypercholesterolemia, hypertriglyceridemia, combined hyperlipidemia, and hypo-HDL cholesterolemia. They can be further classified into: primary hyperlipidemia and secondary hyperlipidemia. The incidence of cardiovascular diseases is gradually increasing in China, and hypercholesterolemia, hypertension and smoking are listed as main risk factors of coronary heart disease. The incidence of coronary heart disease events is increased along with the long-term increase of blood cholesterol, and the blood cholesterol is controlled to be at a proper level for a long time, so that the atherosclerosis can be prevented, the atheromatous plaque can be lightened, and the coronary heart disease events can be reduced. With the deep understanding of the significance of hypertriglyceridemia in atherosclerosis, the prevention and treatment of hyperlipidemia in the majority of people becomes an important link for preventing and treating atherosclerosis.
Chinese patent 201611167389.4 discloses a traditional Chinese medicine formula for treating hyperlipidemia, which comprises the following traditional Chinese medicine components in parts by weight: 13g of dried orange peel, 13g of pinellia ternate, 3g of liquorice, 13g of rhizoma alismatis, 28g of coix seeds, 18g of oriental wormwood, 16g of snakegourd fruit, 13g of scorched hawthorn fruit, 13g of lotus leaf and 13g of radix curcumae, and the preparation and use methods are as follows: decocting with water for oral administration: is taken 1 day, 7 doses are taken as a treatment course, and the administration is required for 2-6 treatment courses. Chinese patent 200910015457.9 discloses a medicine for treating hyperlipidemia, which is prepared from radix Salviae Miltiorrhizae 8-20 parts, folium Nelumbinis 8-20 parts, pericarpium Citri tangerinae 8-20 parts, exocarpium Benincase 8-20 parts, fructus crataegi 5-15 parts, stigma Maydis 5-15 parts, radix Angelicae sinensis 5-15 parts, flos Chrysanthemi root 5-15 parts, semen Cassiae 5-15 parts, herba Apii graveolentis 5-15 parts, fructus Sophorae 3-10 parts, rhizoma Alismatis 3-10 parts, folium Camelliae sinensis 3-10 parts, flos Lupuli 3-10 parts, fructus Mori 3-10 parts, XIAOJINLAMEI 3-10 parts, folium Eriobotryae 3-10 parts, rhizoma Polygonati 2-8 parts, flos Lilii 2-8 parts, fructus Citri Limoniae 2-8 parts, fructus Trichosanthis 2-8 parts, and fructus Aurantii Immaturus 2-8 parts. However, in the prior art, no report is found about the traditional Chinese medicine composition for treating hyperlipoproteinemia.
Disclosure of Invention
The first purpose of the present invention is to provide a Chinese medicine composition for treating hyperlipoproteinemia, which aims at overcoming the defects in the prior art.
The second purpose of the present invention is to provide the use of the above-mentioned Chinese medicinal composition for overcoming the disadvantages of the prior art.
In order to achieve the first purpose, the invention adopts the technical scheme that:
a traditional Chinese medicine composition for treating hyperlipoproteinemia is prepared from the following raw material medicines in parts by weight: 90-110 parts of fructus trichosanthis, 90-110 parts of rhizoma alismatis, 140 parts of raw hawthorn, 90-110 parts of angelica sinensis and 90-110 parts of semen cassiae.
As a preferred embodiment of the invention, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 95-105 parts of fructus trichosanthis, 95-105 parts of rhizoma alismatis, 135 parts of raw hawthorn, 95-105 parts of angelica sinensis and 95-105 parts of semen cassiae.
As a preferred embodiment of the invention, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 100 parts of fructus trichosanthis, 100 parts of rhizoma alismatis, 133 parts of raw hawthorn, 100 parts of angelica sinensis and 100 parts of semen cassiae.
As a preferred embodiment of the invention, the traditional Chinese medicine composition can be prepared into a clinically acceptable pharmaceutical preparation according to a conventional traditional Chinese medicine preparation method.
As a preferred embodiment of the present invention, the pharmaceutical preparation is a pill, powder, granule, capsule, tablet, mixture or oral liquid.
In order to achieve the second object, the invention adopts the technical scheme that:
the application of the traditional Chinese medicine composition in preparing a medicine for treating hyperlipoproteinemia.
As a preferred embodiment of the present invention, the hyperlipoproteinemia is specifically hypercholesterolemia, hypertriglyceridemia, combined hyperlipidemia and low high density lipoprotein cholesterolemia.
As a preferred embodiment of the present invention, the medicament further comprises a pharmaceutically acceptable carrier. Such pharmaceutically acceptable carriers include, but are not limited to: mannitol, sorbitol, sodium metabisulfite, sodium bisulfite, sodium thiosulfate, cysteine hydrochloride, thioglycolic acid, methionine, vitamin C, EDTA disodium, calcium sodium EDTA, monovalent alkali metal carbonates, acetates, phosphates or aqueous solutions thereof, amino acids, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and derivatives thereof, alginates, gelatin, polyvinylpyrrolidone, glycerol, Tween 80, agar, calcium carbonate, calcium bicarbonate, surfactants, polyethylene glycol, cyclodextrin, beta-cyclodextrin, phospholipids, kaolin, talc, calcium stearate, magnesium stearate.
As a preferred embodiment of the present invention, the preparation method of the drug is as follows: the raw material medicaments are taken according to the weight part, water which is 8 to 12 times of the total weight of the medicinal materials is added, the decoction is carried out twice, the filtration is carried out, the filtrate is combined, the supernatant fluid is taken, the concentration is carried out, the preservative and the simple syrup are added, the water is added, and the uniform stirring is carried out, thus obtaining the traditional Chinese medicine.
The invention has the advantages that:
1. the traditional Chinese medicine formula can obviously reduce the serum total cholesterol and triglyceride level of a hyperlipemia animal model, and simultaneously increases the serum HDL-C, so that the traditional Chinese medicine composition has obvious lipid-lowering effect, and the lipid-lowering effect is more obvious under the same dosage level.
2. The traditional Chinese medicine formula of the invention has only 5 medicines, the number of the medicines is small, the preparation method is simple, and the treatment cost is low.
3. In the traditional Chinese medicine formula, the proportion of the traditional Chinese medicine raw materials is obtained by contrast screening of a large number of experiments, and the traditional Chinese medicine formula has the advantages of good curative effect and obvious effect.
4. In the traditional Chinese medicine formula, the snakegourd fruit, the angelica and other traditional Chinese medicines have synergistic effect, so that the lipid-lowering effect of the traditional Chinese medicine composition is remarkably improved, and the curative effect is more remarkable.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
EXAMPLE 1 preparation of the Chinese medicinal composition of the present invention
Taking the following raw material medicines in parts by weight: 100 parts of fructus trichosanthis, 100 parts of rhizoma alismatis, 133 parts of raw hawthorn, 100 parts of angelica sinensis and 100 parts of semen cassiae, and decocting according to a conventional method.
Example 2 preparation of the Chinese medicinal composition of the present invention
Taking the following raw material medicines in parts by weight: 110 parts of fructus trichosanthis, 90 parts of rhizoma alismatis, 130 parts of raw hawthorn, 90 parts of angelica sinensis and 90 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
Example 3 preparation of the Chinese medicinal composition of the present invention
Taking the following raw material medicines in parts by weight: 110 parts of fructus trichosanthis, 110 parts of rhizoma alismatis, 130 parts of raw hawthorn, 90 parts of angelica sinensis and 90 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
Example 4 preparation of the Chinese medicinal composition of the present Invention (IV)
Taking the following raw material medicines in parts by weight: 110 parts of fructus trichosanthis, 110 parts of rhizoma alismatis, 140 parts of raw hawthorn, 90 parts of angelica sinensis and 90 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
Example 5 preparation of the Chinese medicinal composition of the present invention (V)
Taking the following raw material medicines in parts by weight: 110 parts of fructus trichosanthis, 110 parts of rhizoma alismatis, 140 parts of raw hawthorn, 110 parts of angelica sinensis and 90 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
Example 6 preparation of the Chinese medicinal composition of the present invention (VI)
Taking the following raw material medicines in parts by weight: 110 parts of fructus trichosanthis, 110 parts of rhizoma alismatis, 140 parts of raw hawthorn, 110 parts of angelica sinensis and 110 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
EXAMPLE 7 preparation of the Chinese medicinal composition of the present invention (VII)
Taking the following raw material medicines in parts by weight: 110 parts of fructus trichosanthis, 110 parts of rhizoma alismatis, 140 parts of raw hawthorn, 110 parts of angelica sinensis and 110 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
EXAMPLE 8 preparation of the Chinese medicinal composition of the present invention (eight)
Taking the following raw material medicines in parts by weight: 105 parts of fructus trichosanthis, 95 parts of rhizoma alismatis, 130 parts of raw hawthorn, 95 parts of angelica sinensis and 95 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
Example 9 preparation of the Chinese medicinal composition of the present invention (nine)
Taking the following raw material medicines in parts by weight: 105 parts of fructus trichosanthis, 105 parts of rhizoma alismatis, 130 parts of raw hawthorn, 95 parts of angelica sinensis and 95 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
EXAMPLE 10 preparation of the Chinese medicinal composition of the present invention (Ten)
Taking the following raw material medicines in parts by weight: 105 parts of fructus trichosanthis, 105 parts of rhizoma alismatis, 135 parts of raw hawthorn, 95 parts of angelica sinensis and 95 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
EXAMPLE 11 preparation of the Chinese medicinal composition of the present invention (eleven)
Taking the following raw material medicines in parts by weight: 105 parts of fructus trichosanthis, 105 parts of rhizoma alismatis, 135 parts of raw hawthorn, 105 parts of angelica sinensis and 95 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
EXAMPLE 12 preparation of the Chinese medicinal composition of the present invention (twelve)
Taking the following raw material medicines in parts by weight: 105 parts of fructus trichosanthis, 105 parts of rhizoma alismatis, 135 parts of raw hawthorn, 105 parts of angelica sinensis and 105 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
EXAMPLE 13 preparation of the Chinese medicinal composition of the present invention (thirteen)
Taking the following raw material medicines in parts by weight: 105 parts of fructus trichosanthis, 105 parts of rhizoma alismatis, 135 parts of raw hawthorn, 105 parts of angelica sinensis and 105 parts of semen cassiae, and the raw materials are decocted according to a conventional method.
It should be noted that the conventional method for decocting the raw materials described in examples 1 to 13 is a conventional method for preparing a decoction of Chinese herbs, i.e., decocting the raw materials in water to obtain a decoction.
EXAMPLE 14 preparation of tablets/capsules of the Chinese medicinal composition of the present invention
The Chinese medicinal composition of any one of embodiments 1-13 is taken, added with 8-12 times of water, decocted for 1-3 hours, and the decoction is filtered. Adding 10 times of water, decocting for 1.5-2.5 hr, filtering to obtain decoction, mixing decoctions, standing, filtering to obtain supernatant, concentrating, cooling, adding 1-5 times of ethanol, stirring, and precipitating overnight. Taking supernatant, and concentrating to obtain thick extract; adding pharmaceutical adjuvants, vacuum drying, pulverizing, granulating, and making into tablet or capsule.
Example 15 preparation of a Chinese medicinal composition/oral liquid of the present invention
The Chinese medicinal composition of any one of embodiments 1 to 13 is taken, added with 8 to 10 times of water, decocted for 3 hours, and the decoction is filtered. Adding 8 times of water, decocting for 2 hr, filtering to obtain decoction, mixing the decoctions, standing, filtering to obtain supernatant, concentrating, cooling, adding 1-5 times of ethanol, stirring, and precipitating overnight. Taking supernatant, and concentrating to obtain thick extract; adding appropriate pharmaceutical adjuvants, and making into mixture, oral liquid or syrup.
EXAMPLE 16 preparation of granules of the Chinese medicinal composition of the present invention
The Chinese medicinal composition of any one of embodiments 1 to 13 is taken, added with 8 to 10 times of water, decocted for 2.5 to 3.5 hours and filtered to obtain decoction. Adding 10 times of water, decocting for 2 hr, filtering to obtain decoction, mixing the decoctions, standing, filtering to obtain supernatant, concentrating, cooling, adding 1-5 times of ethanol, stirring, and precipitating overnight. Taking supernatant, and concentrating to obtain thick extract; adding appropriate pharmaceutical adjuvants, granulating, drying, grading to obtain 20g granule, and packaging into 10 g/bag.
EXAMPLE 17 preparation of syrup of the Chinese medicinal composition of the present invention
Taking the traditional Chinese medicine composition of any one of embodiments 1-13, adding water with the amount of 8-10 times of the total amount of medicinal materials, decocting twice, the first time for 2 hours, the second time for 1 hour, filtering, combining the filtrates, standing the filtrate for more than 12 hours, taking the supernatant, concentrating to a proper amount, adding a preservative and simple syrup while hot, adding water to 1000ml, stirring uniformly, subpackaging, and autoclaving to obtain the traditional Chinese medicine composition.
EXAMPLE 18 pharmacodynamic experiment
1. Material
SD male rats, weight 150-. The invention relates to a traditional Chinese medicine composition. Zhikeqing capsule (Chinese medicine Z20043852, Dongguan Wan Cheng pharmaceutical Co., Ltd., 0.3g per capsule). High-fat feed: 79% basal feed, 1% cholesterol, 10% egg yolk powder and 10% lard. Total Cholesterol (TC), Triglyceride (TG), and high density lipoprotein cholesterol (HDL-C) from Shanghai Jing union Biotechnology, Inc.
2. Method of producing a composite material
After the basic feed is fed to rats for 5 days, tail blood is taken overnight on an empty stomach, serum TC, TG and HDL-C are measured, the blood is randomly divided into 5 groups which are respectively a blank control group, a model group, a positive control group, a traditional Chinese medicine 1 group and a traditional Chinese medicine 2 group, the basic feed is fed to all the groups except the blank control group, and the high-fat feed is fed to all the groups except the blank control group, and the administration group is simultaneously administered by intragastric administration for 1 time per day for 8 weeks continuously. After 21h of administration (fasting after administration) at week 4 and week 8, respectively, tail blood was taken and the TC, TG, and HDL-C contents in the serum were measured.
The dosing regimen was as follows:
the positive control group was administered with Likeqing capsule (0.4 g/kg).
The following Chinese medicinal compositions are administered to the Chinese medicinal 1 group: 100 parts of fructus trichosanthis, 100 parts of rhizoma alismatis, 133 parts of raw hawthorn, 100 parts of angelica and 100 parts of semen cassiae, adding water accounting for 8-12 times of the total amount of medicinal materials, decocting twice, decocting for 2 hours for the first time and 1 hour for the second time, filtering, combining filtrates, standing for more than 12 hours, taking supernate, concentrating until the concentration of the medicinal materials is 0.2-0.8g/ml, and subpackaging for later use.
The Chinese medicinal composition is administered to the Chinese medicinal 2 groups as follows: 120 parts of fructus trichosanthis, 120 parts of rhizoma alismatis, 120 parts of raw hawthorn, 120 parts of angelica sinensis and 120 parts of semen cassiae, adding water accounting for 8-12 times of the total amount of medicinal materials, decocting twice, decocting for 2 hours for the first time and 1 hour for the second time, filtering, combining filtrates, standing for more than 12 hours, taking supernate, concentrating until the concentration of the medicinal materials is 0.2-0.8g/ml, and subpackaging for later use.
3. Results
(1) The drug of the invention has the effect of reducing TC and TG in rat serum
As shown in Table 1, comparison of TC levels before treatment in each group showed no statistical significance (P >0.05) in the differences, indicating that the total cholesterol levels remained consistent before treatment in each group of rats. After 4 weeks of treatment, the traditional Chinese medicine and the positive control group have obvious effect of reducing serum TC and TG of the hyperlipidemic rat, wherein the traditional Chinese medicine 1 group has better effect compared with the positive control group. After 8 weeks of treatment, the traditional Chinese medicine and the positive control group have obvious reducing effect on serum TC and TG of the hyperlipidemic rat, wherein the traditional Chinese medicine 1 group has obvious effect compared with the positive control group. The results show that the traditional Chinese medicine 1 group has better effect on reducing the serum TC and TG of the hyperlipidemic rat.
TABLE 1 serum TC, TG levels in pre-experimental and treated 4, 8 week high-fat rats
Note: p <0.01 in comparison to the cohort model, P <0.05 in comparison to the cohort model, and P <0.05 in comparison to the cohort positive control.
(2) Effect of the drug of the present invention on rat serum HDL-C
As shown in Table 2, the comparison of the HDL-C content before treatment in each group shows that the difference is not statistically significant (P >0.05), which indicates that the HDL-C content before treatment in each group of rats is consistent. After 4 weeks of treatment, the effects of the traditional Chinese medicine 1 group and a positive control drug on the serum HDL-C of the rat with the hyperlipidemia are remarkably different, and the level of the serum HDL-C can be effectively controlled, wherein the control effect of the traditional Chinese medicine 1 group is better compared with that of the positive control group. After 8 weeks of treatment, the effects of the traditional Chinese medicine 1 group, the traditional Chinese medicine 2 group and the positive control medicine on the serum HDL-C of the rat with the hyperlipidemia are all significantly different, and the level of the serum HDL-C can be effectively controlled. The results show that the traditional Chinese medicine 1 group has better effect of controlling the serum HDL-C of the rat with the hyperlipidemia.
TABLE 2 serum HDL-C levels in high-fat rats before the experiment and after 4 and 8 weeks of treatment
Note: p <0.01 in comparison to the cohort model, P <0.05 in comparison to the cohort model, and P <0.05 in comparison to the cohort positive control.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (6)
1. A traditional Chinese medicine composition for preventing serum total cholesterol and triglyceride increase and high density lipoprotein cholesterol decrease caused by high fat diet, reducing serum total cholesterol and triglyceride content and improving high density lipoprotein cholesterol content is characterized by being prepared from the following raw material medicines in parts by weight: 100 parts of fructus trichosanthis, 100 parts of rhizoma alismatis, 133 parts of raw hawthorn, 100 parts of angelica sinensis and 100 parts of semen cassiae.
2. The traditional Chinese medicine composition of claim 1, which is prepared into a clinically acceptable pharmaceutical preparation according to a conventional traditional Chinese medicine preparation method.
3. The composition of claim 2, wherein the pharmaceutical formulation is a pill, powder, granule, capsule, tablet or mixture.
4. The use of the composition of claim 1 in the preparation of a medicament for preventing elevated serum total cholesterol and triglycerides, reduced high density lipoprotein cholesterol, and lowering serum total cholesterol and triglycerides, and increasing high density lipoprotein cholesterol levels in a high fat diet.
5. The use of claim 4, wherein the medicament further comprises a pharmaceutically acceptable carrier.
6. The use according to claim 4, wherein the medicament is prepared by the following process: the raw material medicaments are taken according to the weight part, water which is 8 to 12 times of the total weight of the medicinal materials is added, the decoction is carried out twice, the filtration is carried out, the filtrate is combined, the supernatant fluid is taken, the concentration is carried out, the preservative and the simple syrup are added, the water is added, and the uniform stirring is carried out, thus obtaining the traditional Chinese medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710877861.1A CN107536921B (en) | 2017-09-26 | 2017-09-26 | Traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710877861.1A CN107536921B (en) | 2017-09-26 | 2017-09-26 | Traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107536921A CN107536921A (en) | 2018-01-05 |
| CN107536921B true CN107536921B (en) | 2021-04-30 |
Family
ID=60964417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710877861.1A Expired - Fee Related CN107536921B (en) | 2017-09-26 | 2017-09-26 | Traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107536921B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112315349B (en) * | 2020-11-19 | 2022-03-11 | 江西大家食品有限公司 | Egg white separating device based on vibration dish |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1600359A (en) * | 2004-07-06 | 2005-03-30 | 谢子龙 | Capsule for curing high blood fat and preparation method |
-
2017
- 2017-09-26 CN CN201710877861.1A patent/CN107536921B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN107536921A (en) | 2018-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100502936C (en) | Chinese medicinal compound preparation for inhibiting tumor and resisting insenescence | |
| JP2004161732A (en) | Natural medicine preparation for treatment of hiv/aids patient | |
| CN105362340B (en) | A kind of pharmaceutical composition for treating leukaemia and preparation method thereof | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN1935194B (en) | Preparation method of Chinese medicine composition for treating nephroma | |
| CN107536921B (en) | Traditional Chinese medicine composition for treating hyperlipoproteinemia and application thereof | |
| CN101461932B (en) | Medicament composition for treating children's damp-heat diarrhea induced by spleen insufficiency and preparation method thereof | |
| CN1709326A (en) | Method for preparing concentrated pill for treating mammary gland proliferation disease | |
| CN118434431A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101024066A (en) | Jinsangliyan preparation and preparing method | |
| CN106309729B (en) | A kind of Chinese medicine composition adjusting chronic hepatitis immune function | |
| CN105362776A (en) | Traditional Chinese medicinal composition for treating hyperthyroidism as well as preparation method and application of traditional Chinese medicinal composition | |
| CN101491628B (en) | Lycium-rehmannia preparation preparation method | |
| CN110755601B (en) | Kidney bean lectin plant medicine composition for treating HIV/AIDS immune reconstruction defect and preparation method and application thereof | |
| CN101024060B (en) | Jinsangsanjie preparation preparing method | |
| CN1517115A (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
| CN114796432B (en) | Traditional Chinese medicine composition for treating gastritis and preparation method thereof | |
| CN1321630C (en) | Method for preparing blood flow cutting off dispersing tablet | |
| JPH09136839A (en) | Composition having physiological activity and its production | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104666992B (en) | The Chinese medicine composition that hepatic and renal function caused by a kind of mitigation AIDS antiviral drugs damages | |
| CN114028449B (en) | Traditional Chinese medicine compound medicine for treating fatty liver disease | |
| CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
| CN103372114B (en) | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210430 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |